Alvedia’s History

Founded in 2010 Alvedia is a family business where innovation in veterinary transfusion medicine
is led by the scientific expertise of Pr Dominique Rigal and the entrepreneurial vision of Alice Rigal.

“Our strength lies in our shared vision and values, which emphasize the reliability of our technologies”

Pr Dominique Rigal
Co-founder and CSO

With his prestigious background in human medicine and blood banking, Dominique brought the transformative technology of human blood typing and human Gel Test method to the company.

Dominique is behind the development of the complete range of canine, feline and equine blood group monoclonal antibodies. These highly specific antibodies improve the safety and effectiveness of animal blood transfusions by ensuring compatibility between donors and recipients, thus preventing the risk of transfusion reactions.

“Our strength lies in our shared vision and values, which emphasize the reliability of our technologies”

Alice Rigal Co-founder & CEO Alvedia

Alice Rigal
Co-founder and CEO

With a rich international management experience, mainly in the USA and Switzerland, Alice is driving Alvedia to global recognition through a personal investment in the success and reputation of the business.

“The aim is to pursue excellence and maintain high standards in our operations, product reliability and scientific support for our clients worldwide”

This support likely includes everything from detailed product information and usage guidelines to troubleshooting and ongoing research findings, which can be critical for practitioners in the field.

Our Product Range Development

2011

Alvedia Blood Typing QuickTest & LabTest

2013

First in-clinic Canine
COOMBS Test (DAT)

2015

Canine Crossmatch Test
(XM) launched

2019

Feline Crossmatch Test
(XM) launched

2021

First in-clinic Feline
COOMBS Test (DAT)

2022

Gel Test Technology
for DAT and XM

2023

The Test Reader Application
is launched